Skip to content
DataLookout
Menu

ENABLE-2NCT07905183

A Study of ELVN-001 Versus Investigator-Selected TKI, in CP-CML Previously Treated With One or More TKIs

StatusRecruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Recruitment opened
    • Trial sites expanded: 0 → 4 locations
    • Study title shortened, about 1 word
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Major Molecular Response (MMR) Rate at Week 24 - ELVN-001 versus Investigator-selected TKI
Timeframe: 24 weeks

Secondary (14)

Major Molecular Response (MMR) Rate at Week 96 - ELVN-001 versus Investigator-selected TKI
Change in overall scores, individual scales, and health status based on participant reporting - ELVN-001 versus Investigator-selected TKI
Major Molecular Response (MMR) at all scheduled collection time points - ELVN-001 versus Investigator-selected TKI
Major Molecular Response (MMR) by all scheduled collection time points - ELVN-001 versus Investigator-selected TKI
Time to Major Molecular Response (MMR) - ELVN-001 versus Investigator-selected TKI
Show 9 moreShow less
Duration of Major Molecular Response (MMR) - ELVN-001 versus Investigator-selected TKI
BCR::ABL1 ratio ≤ 1% at and by all scheduled data collection time points - ELVN-001 versus Investigator-selected TKI
Time to treatment failure - ELVN-001 versus Investigator-selected TKI
Progression-free survival - ELVN-001 versus Investigator-selected TKI
Overall survival (OS) - ELVN-001 versus Investigator-selected TKI
MR4 and MR4.5 at and by all scheduled data collection time points - ELVN-001 versus Investigator-selected TKI
Time to treatment discontinuation due to adverse event (AE) - ELVN-001 versus Investigator-selected TKI
Characterization of adverse events (AE) and clinically relevant findings, including laboratory abnormalities, electrocardiogram (ECG) changes, and other safety data - ELVN-001 versus Investigator-selected TKI
Plasma concentrations of ELVN-001 in participants treated with ELVN-001 will be assessed at all scheduled collection timepoints

Arms and interventions

ELVN-001Experimental

ELVN-001

Investigator-selected TKIActive comparator

Randomized to receive one of the following investigator's choice TKIs: Dasatinib, Nilotinib, or Bosutinib

Drugs: ELVN-001, TKI

Sites

4 sites in 1 country